Claims for Patent: 10,857,162

Summary for Patent: 10,857,162

Title:	Compositions for improving cell viability and methods of use thereof
Abstract:	This invention relates to methods and compositions for use improving cell viability, particularly neural cell viability, and more particularly to methods and compositions for use improving cell viability by reducing reactive oxygen metabolite-mediated oxidative damage in a cell, regulating redox homeostasis in a cell, or reducing mitochondrial dysfunction in a cell. The invention further relates to the administration of the bile acid tauroursodeoxycholic acid (TUDCA) in combination with phenylbutyric Acid (PBA) to improve cell viability, and treat at least one symptom associated with, prevent the time of onset of, or slow the development of a disease related to oxidative stress.
Inventor(s):	Cohen Joshua, Klee Justin
Assignee:	Amylyx Pharmaceuticals Inc.
Application Number:	US16781239
Patent Claims:	2. The method of claim 1 , wherein the TUDCA is administered once a day.3. The method of claim 1 , wherein the sodium phenylbutyrate is administered once a day.4. The method of claim 1 , wherein the TUDCA and the sodium phenylbutyrate are administered once a day.5. The method of claim 1 , wherein the TUDCA and sodium phenylbutyrate are administered as separate dosage forms.6. The method of claim 1 , wherein the TUDCA and sodium phenylbutyrate are administered in a single dosage form.7. The method of claim 1 , wherein the TUDCA is administered at an amount of about 0.5 to about 5 grams per day.8. The method of claim 1 , wherein the TUDCA is administered at an amount of about 1.5 to about 2.5 grams per day.9. The method of claim 1 , wherein the TUDCA is administered at an amount of 1 gram twice a day.10. The method of claim 1 , wherein the sodium phenylbutyrate is administered at an amount of about 0.5 to about 10 grams per day.11. The method of claim 1 , wherein the sodium phenylbutyrate is administered at an amount of about 4.5 to about 8.5 grams per day.12. The method of claim 1 , wherein the sodium phenylbutyrate is administered at an amount of 3 grams twice a day.13. The method of claim 1 , wherein the TUDCA and the sodium phenylbutyrate are administered to the subject for less than 6 months.14. The method of claim 1 , wherein the TUDCA and the sodium phenylbutyrate are administered to the subject for less than 3 months.15. The method of claim 1 , wherein the TUDCA and the sodium phenylbutyrate are administered to the subject for at least 6 months.16. The method of claim 1 , wherein the administering is oral administration.17. The method of claim 1 , wherein the human subject is suspected as having ALS.18. The method of claim 1 , wherein the human subject has been diagnosed as having a condition associated with ALS.19. The method of claim 1 , wherein the TUDCA is administered at an amount of 1 gram twice a day and the sodium phenylbutyrate is administered at an amount of 3 grams twice a day claim 1 , wherein the TUDCA and sodium phenylbutyrate are administered in a single dosage form claim 1 , and wherein the administering is oral administration.20. The method of claim 1 , wherein the TUDCA is administered twice a day.21. The method of claim 1 , wherein the sodium phenylbutyrate is administered twice a day.22. The method of claim 1 , wherein the TUDCA and the sodium phenylbutyrate are administered twice a day.